KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Operating Income (2016 - 2025)

Historic Operating Income for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to -$2.6 billion.

  • Bristol Myers Squibb's Operating Income rose 4334.7% to -$2.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.6 billion, marking a year-over-year increase of 7937.53%. This contributed to the annual value of -$4.6 billion for FY2025, which is 7937.98% up from last year.
  • Bristol Myers Squibb's Operating Income amounted to -$2.6 billion in Q4 2025, which was up 4334.7% from -$321.0 million recorded in Q3 2025.
  • Bristol Myers Squibb's 5-year Operating Income high stood at $204.0 million for Q1 2023, and its period low was -$14.4 billion during Q1 2024.
  • Its 5-year average for Operating Income is -$1.7 billion, with a median of -$773.0 million in 2022.
  • Its Operating Income has fluctuated over the past 5 years, first soared by 12602.04% in 2023, then plummeted by 718235.29% in 2024.
  • Over the past 5 years, Bristol Myers Squibb's Operating Income (Quarter) stood at -$498.0 million in 2021, then tumbled by 47.39% to -$734.0 million in 2022, then tumbled by 45.91% to -$1.1 billion in 2023, then crashed by 332.96% to -$4.6 billion in 2024, then soared by 43.35% to -$2.6 billion in 2025.
  • Its last three reported values are -$2.6 billion in Q4 2025, -$321.0 million for Q3 2025, and -$1.6 billion during Q2 2025.